Efficacy of the ATl-angiotensin receptor blocker eprosartan in patients with arterial hypertension in the different functional state of the renin-angiotensin-aldesterone system

The purpose of the study was to examine the effects of the AT 1 -angiotensin receptor blocker eprosartan (Teveten, “Solvay Pharma”) on the level of blood pressure (BP) as compared with the functional state of the renin-angiotensin-aldosterone system in patients with arterial hypertension (AH) of different genesis. Eprosartan was given in a daily dose of 600 mg for 8 weeks. If there was no normalization of BP or achievement of its target level, the therapy was supplemented by hypothiazide in a dose of 25 mg. Thirty-thirty hypertensive patients with symptomatic BP of renal genesis. Clinical BP measurements indicated that 8-week eprosartan therapy caused a 10 mm Hg or more reduction in systolic BP in 26 (78,8%) patients, systolic BP becoming normal (less than 140 mm Hg) in 21 (63,6%) patients and diastolic BP (less than 90 mm Hg) in 23 (69,7%). Analyzing the antihypertensive effect of eprosartan in relation to the severity of AH has established that eprosartan significantly lowers BP in the groups of mild [143±3,42/86±4,25 mm Hg before treatment, 118±2,56/75±3,54 mm Hg (p<0,001) after treatment], moderate [151±2,9/94±2,81 mm Hg before treatment, 128±3,24/81±2,14 mm Hg (p<0,001) after treatment], and severe [199±3,1/116±2,51 mm Hg before treatment, l63±3,32/95±3,62 mm Hg (p<0,001) after treatment] forms of AH. At the same time the best effect was achieved in patients with mild and moderate forms of AH. Examining the renin-angiotensin-aldosterone system during therapy with eprosartan as compared to its antihypertensive effect has revealed a significant decrease in BP after 8-week therapy both in patients with normal and higher activity of renin (a decrease in systolic BP by 30.0±4,97 mm Hg and in diastolic BP by 16,8±7,8 mm Hg, p<0,001) and in diastolic BP by 16,8±7,8 mmHg, p < 0,001) and in those with low-renin form of AHby 14,2±2,34 mm Hg, p<0,001).The findings suggest that AT j-angiotensin receptor blockers are beneficial not only in hypertensive patients with high and normal ARP but also in those with ARP, which expands the field of their clinical use.